NCT00742001

Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival

IMPROVE: Inactivation of Whole Blood With Mirasol (R): Performance in Red Blood Cells, Platelets and Plasma Investigation

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Terumo BCTbio · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Feasibility trial to evaluate recovery and survival of red blood cells (RBCs) from Mirasol-treated whole blood

Detailed description

Radiolabeling of red blood cells (RBCs) followed by infusion back to the donor is commonly used to test the quality of RBCs in a person. By measuring the level of radioisotope in a blood sample, these tests evaluate what percentage of the RBCs remain in the bloodstream after 24 hours (recovery) and can predict how long the RBCs will remain in circulation (survival). The IMPROVE trial is a feasibility trial to evaluate these parameters in RBCs obtained from whole blood units that have been treated with the Mirasol System.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	Mirasol System for Whole Blood.	Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects

Timeline

• Start date: 2008-09-10
• Primary completion: 2008-11-20
• Completion: 2008-12-16
• First posted: 2008-08-27
• Last updated: 2019-08-28
• Results posted: 2019-08-28

Locations

1 site across 1 country: United States